Chimerix (NASDAQ:CMRX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Chimerix (NASDAQ:CMRX) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04), Zacks reports. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 37.93%. During the same quarter last year, the company posted ($0.24) earnings per share.

Chimerix Stock Performance

CMRX traded up $0.02 on Thursday, hitting $0.97. 227,598 shares of the company were exchanged, compared to its average volume of 384,074. The business’s fifty day moving average is $1.05 and its 200 day moving average is $1.00. Chimerix has a fifty-two week low of $0.88 and a fifty-two week high of $1.57. The firm has a market capitalization of $86.94 million, a P/E ratio of -1.04 and a beta of 1.13.

Analyst Upgrades and Downgrades

CMRX has been the subject of a number of research reports. StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Monday, March 4th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research note on Friday, March 1st. Finally, Wedbush restated an “outperform” rating and issued a $6.00 price objective on shares of Chimerix in a research note on Monday, February 12th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.